Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

Next Previous
Trial Profile

A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of TAK-491 With Valsartan in Chinese Subjects With Essential Hypertension

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Valsartan
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Acronyms CONSORT-compliant
  • Sponsors Takeda

Most Recent Events

  • 07 Aug 2020 Primary endpoint (Change from baseline to week 8 in trough Sitting Clinic Systolic Blood Pressure (SBP): AZL-M 40-mg group to 160-mg valsartan group), has been met according to results published in the Medicine
  • 07 Aug 2020 Primary endpoint (Change from baseline to week 8 in trough Sitting Clinic Systolic Blood Pressure (SBP): AZL-M 80-mg group to valsartan 160-mg group), has been met according to results published in the Medicine
  • 07 Aug 2020 Results published in the Medicine

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top